Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

A Florida Highway Patrol trooper fatally shot a suspect during an altercation at a central Florida hospital on Friday, ...

Cal Fire aircraft have repeatedly dipped into Otay Lake, preparing to drop that water onto the 4,000+ acre fire.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...